Syndax Pharmaceuticals, Inc. SNDX
Set alert
13.65 USD -0.50 -3.53%
At close
13.81 +0.16 +1.17%
Pre-market · Nov 2, 5:00 AM ET
13.62 Day range 14.35
12.80 52-week range 25.59
- YTD
- -35.03%
- 1 year
- -0.36%
- Open
- 14.06
- Prev close
- 14.15
- Mkt cap
- 1.21B
- Vol
- 2.54M
- Avg vol
- 1.96M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.62
- High
- 14.35
- Forward P/E
- -16.27
- Beta
- 0.42
- Short ratio
- 8.03
- Inst. own
- 126.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 17.30
- 200-d avg
- 20.27
- 1y target
- 37.27
2Y chart
Events in this range
- Aug 4, 2025Earnings: -0.83; estimate -1; surprise 17%
- Nov 3, 2025Earnings: -0.7; estimate -0.74; surprise 5.41%
- Feb 26, 2026Earnings: -0.78; estimate -0.58404; surprise -33.55%
- Apr 30, 2026Earnings: -0.48; estimate -0.59; surprise 18.64%
- Jun 12, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 4, 2026Earnings: -0.55; estimate -0.44767; surprise -22.86%
- Aug 5, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 11, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 21, 2026Rating: UBS · Buy → Buy
- Oct 13, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (69)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| RSI: Oversold | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 22, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| RSI: Overbought | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 27, 2026 | 8 months ago |
| SMA: Bearish | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 13, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 5, 2025 | 12 months ago |
| MACD: Buy Signal | Nov 5, 2025 | 12 months ago |
| SMA: Bullish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 12, 2025 | 1 year ago |
| RSI: Overbought | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| SMA: Bullish | Jul 29, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
| RSI: Oversold | Dec 12, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.21B
- Enterprise value
- 1.30B
- Trailing P/E
- 0.00
- Forward P/E
- -16.27
- PEG ratio
- 0.00
- Price / sales
- 4.79
- Price / book
- 80.77
- EPS (TTM)
- -2.52
- Beta
- 0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -87.52%
- Revenue (TTM)
- 252.25M
- Revenue growth
- 91.80%
- Free cash flow
- -150.08M
- Total cash
- 554.27M
- Total debt
- 589.38M
- Return on equity
- -255.93%
- Shares outstanding
- 88.61M
- Short % of float
- 20.51%
- 50-day average
- 17.30
- 200-day average
- 20.27
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.27 +173.1% upside
Now 13.65
- Target (low)
- 23.00
- Target (mean)
- 37.27
- Target (high)
- 57.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy2
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -0.48287.
Financials — quick view
SNDX Revenue — quarterly 72.79M
SNDX Net income — quarterly -49.36M
SNDX EPS — quarterly -0.55
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.4928 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.44767 | -0.55 | -0.10 | -22.86% |
| Apr 30, 2026 | Mar 31, 2026 | -0.59 | -0.48 | +0.11 | +18.64% |
| Feb 26, 2026 | Dec 31, 2025 | -0.58404 | -0.78 | -0.20 | -33.55% |
| Nov 3, 2025 | Sep 30, 2025 | -0.74 | -0.70 | +0.04 | +5.41% |
| Aug 4, 2025 | Jun 30, 2025 | -1.00 | -0.83 | +0.17 | +17.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2026 | UBS | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syndax.com
News
- Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Syndax Announces Participation in November Investor Conferences
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
- Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
- Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday
- Syndax Pharmaceuticals Suffers Pipeline Blow
- Crude Oil Edges Higher; Citigroup Earnings Top Views
- Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
Your note
Sign in to keep a note on SNDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOTWOOD NICHOLAS A.J. | Officer | Conversion of Exercise of derivative security | Jun 11, 2026 | 60,885 |
| GALLAGHER NEIL | Officer | Sale | Feb 9, 2025 | 85,095 |
| GOLDAN KEITH ALAN | Chief Financial Officer | Sale | May 31, 2026 | 139,252 |
| HUBER MARTIN H JR | Director | Stock Award(Grant) | Feb 3, 2026 | 103,000 |
| JARRETT A JENNIFER | Director | Stock Award(Grant) | Feb 3, 2026 | 114,000 |
| KATKIN KEITH A | Director | Stock Award(Grant) | Feb 3, 2026 | 124,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.18% | 9,020,006 | 123.12M | Jun 29, 2026 |
| Kynam Capital Management, LP | 9.09% | 8,050,959 | 109.90M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.61% | 5,861,265 | 80.01M | Jun 29, 2026 |
| State Street Corporation | 6.39% | 5,658,424 | 77.24M | Jun 29, 2026 |
| Bank of America Corporation | 4.57% | 4,045,094 | 55.22M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.43% | 3,927,892 | 53.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 2,823,912 | 38.55M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.87% | 2,547,266 | 34.77M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,296,035 | 31.34M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.37% | 1,211,108 | 16.53M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 1,013,559 | 13.84M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.10% | 971,932 | 13.27M | Jul 30, 2026 |